SCHEMBL993214

SCHEMBL993214

O[CH]C(O)C(O)C(O)CO

nearest known ligand 0.56

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
TDP1 Q9NUW8 1/20 0.53
KDM4E B2RXH2 2/20 0.39
PDE4A P27815 1/20 0.39
USP2 O75604 1/20 0.36
SLCO1B1 Q9Y6L6 1/20 0.36
ALDH1A1 P00352 2/20 0.32
TOP1 P11387 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19304988 0.92 LMNA (0.61) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL8720778 0.92 LMNA (0.61) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL1867849 0.81
SCHEMBL6935516 0.81
SCHEMBL29508718 0.78 LMNA (0.50) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL23497716 0.74 LMNA (0.53) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL6435544 0.74 TSHR (0.33) ALDH1A1
SCHEMBL23497770 0.74 LMNA (0.53) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL5146599 0.74 LMNA (0.53) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL3089641 0.74 LMNA (0.53) LMNAL3MBTL1TDP1KDM4EPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118307846-A Organic-inorganic hybridized nano clay and preparation method and application thereof 合肥中科科乐新材料有限责任公司 2024-07-09 CN claimed
US-9644140-B2 Method of reducing dust with particulates coated with a polycationic polymer BAKER HUGHES INCORPORATED (US) 2017-05-09 US claimed
US-9624377-B2 Methods of using sand composites to control dust BAKER HUGHES INCORPORATED (US) 2017-04-18 US claimed
US-20150104647-A1 SAND COMPOSITES AND METHODS OF USING THE SAME TO CONTROL DUST BAKER HUGHES HOLDINGS LLC 2015-04-16 US claimed
US-20150047848-A1 METHOD OF REDUCING DUST WITH PARTICULATES COATED WITH A POLYCATIONIC POLYMER BAKER HUGHES HOLDINGS LLC 2015-02-19 US claimed
US-6232469-B1 FOR DYES, POLYMERS FUJI PHOTO FILM CO., LTD. (JP) 2001-05-15 US claimed
US-5981600-A Hydroxyanthraquinone derivatives BAYKUT FIKRET (TR) 1999-11-09 US claimed
EP-0369944-A1 Substituted oxadiamino butanes CIBA-GEIGY AG (CH) 1990-05-23 EP claimed
CN-118307846-A Organic-inorganic hybridized nano clay and preparation method and application thereof 合肥中科科乐新材料有限责任公司 2024-07-09 CN disclosed
WO-2024076715-A1 METHODS AND COMPOSITIONS RELATING TO IMPROVED IONIC LIQUID ADJUVANTS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-04-11 WO disclosed
US-20240016735-A1 IONIC LIQUIDS FOR DRUG DELIVERY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-01-18 US disclosed
CN-115996751-A Methods and compositions relating to ionic liquid adjuvants 哈佛大学校长及研究员协会 2023-04-21 CN disclosed
US-20230102247-A1 METHODS AND COMPOSITIONS RELATING TO IONIC LIQUID ADJUVANTS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-03-30 US disclosed
EP-4142787-A1 METHODS AND COMPOSITIONS RELATING TO IONIC LIQUID ADJUVANTS President And Fellows Of Harvard College (US) 2023-03-08 EP disclosed
EP-0691327-A1 AMINE DERIVATIVE AND DERMATOLOGIC PREPARATION CONTAINING THE SAME Kao Corporation (JP) 1996-01-10 EP disclosed
EP-0605543-A1 COMPOSITION FOR EXTERNAL SKIN CARE. KAO CORP (JP) 1994-07-13 EP disclosed
WO-1993005763-A1 COMPOSITION FOR EXTERNAL SKIN CARE KAO CORPORATION (JP) 1993-04-01 WO disclosed
US-5169867-A Antitumor agents, anticarcinogenic agents CIBA-GEIGY CORPORATION (US) 1992-12-08 US disclosed
EP-0452264-A1 Hydroxylamine compounds CIBA-GEIGY AG (CH) 1991-10-16 EP disclosed
EP-0369944-A1 Substituted oxadiamino butanes CIBA-GEIGY AG (CH) 1990-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016735-A1 IONIC LIQUIDS FOR DRUG DELIVERY SLCO4C1, SLC47A1, ABCB11 LMNA 725/4885L3MBTL1 167/4885TDP1 2194/4885
US-20230102247-A1 METHODS AND COMPOSITIONS RELATING TO IONIC LIQUID ADJUVANTS MYD88, TLR7, TLR9 LMNA 1658/4885L3MBTL1 1368/4885TDP1 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.